大麻二酚在医学上的应用前景

蒋鸿雁; 张瑞林; 曹艳; 吴海鹰; 李坪

doi:10.12259/j.issn.2095-610X.S20210208

大麻二酚在医学上的应用前景

doi: 10.12259/j.issn.2095-610X.S20210208

蒋鸿雁^{1, 4},
张瑞林²,
曹艳¹,
吴海鹰³,
李坪^1, ,

1.
昆明医科大学人体解剖学与组织胚胎学系
2.
法医学院毒物化学系，云南昆明　650500
3.
昆明医科大学第一附属医院急诊医学部，云南昆明　650032
4.
遂宁市中心医院病理科，四川遂宁　629000

基金项目: 国家自然科学基金资助项目（82060241，82002002，81960817）；云南省科技创新团队基金资助项目（2019HC014）

详细信息

作者简介:
蒋鸿雁（1993～），女，四川遂宁人，在读硕士研究生，主要从事人体解剖学与组织胚胎学研究工作

通讯作者:
李坪，E-mail：kyzplp@163.com

中图分类号: R93
计量
- 文章访问数: 1990
- HTML全文浏览量: 1797
- PDF下载量: 24
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-14
- 刊出日期: 2021-03-05

Application Prospect of Mannabidiol in Medicine

1.
Dept. of Human Anatomy and Histology and Embryology，Kunming Medical University
2.
Dept. of Toxicology，School of Forensic Medicine
3.
Dept. of Emergency Medicine，First Affiliated Hospital，Kunming Yunnan 650032
4.
Dept. of Pathology，Suining Central Hospital，Suining Sichuan，China

摘要

摘要: 大麻中具有药用价值的主要成分是Δ9-四氢大麻酚（Δ9-THC）和大麻二酚（CBD），其中CBD因不能直接激活大麻素1型受体（CB1R）和大麻素2型受体（CB2R）而不具有精神活性和药物依赖性，安全性相对高。CBD作为主要的大麻素提取物，证实具有镇痛、镇静、抗炎、抗惊厥、改善睡眠、抗焦虑、抗精神病、抗风湿、保护皮肤屏障、抗细胞凋亡和神经保护等作用。本综述旨在总结CBD在临床疾病治疗中的应用现状，为今后CBD相关药物在治疗癫痫、神经病理性疼痛、焦虑症和抑郁症、肿瘤、皮肤、代谢相关疾病的应用提供新思路。
- 大麻二酚 /
- 临床应用 /
- 神经保护作用
Abstract: The main components of cannabis with medicinal value are Δ9-tetrahydrocannabinol（Δ9-THC）and cannabidiol（CBD）, of which CBD cannot directly activate cannabinoid type 1 receptor（CB1R）and cannabinoid type 2 receptors. Body（CB2R）does not have psychoactive and drug dependence, and its safety is relatively high. CBD, as the main cannabinoid extract, has proven to have analgesic, sedative, anti-inflammatory, anti-convulsant, sleep-improving, anti-anxiety, anti-psychotic, anti-rheumatic, skin barrier, anti-apoptotic and neuroprotective effects. This review aims to summarize the application status of CBD in the treatment of clinical diseases, and provide new ideas for the future application of CBD-related drugs in the treatment of epilepsy, neuropathic pain, anxiety and depression, tumors, skin, and metabolism-related diseases.
- Cannabidiol /
- Clinical application /
- Neuroprotection

HTML全文

参考文献(49)

[1]	Devinsky O,Marsh E,Friedman D,et al. Cannabidiol in patients with treatment-resistant epilepsy:an open-label interventional trial[J]. The Lancet Neurology,2016,15(3):270-278. doi: 10.1016/S1474-4422(15)00379-8
[2]	Stockings E,Zagic D,Campbell G,et al. Evidence for cannabis and cannabinoids for epilepsy:a systematic review of controlled and observational evidence[J]. Journal of Neurology,Neurosurgery,and Psychiatry,2018,89(7):741-753. doi: 10.1136/jnnp-2017-317168
[3]	Rosenberg E C,Louik J,Conway E,et al. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective,open-label clinical study with cannabidiol[J]. Epilepsia,2017,58(8):e96-e100. doi: 10.1111/epi.13815
[4]	Ferreira-junior N C,Campos A C,Guimarães F S,et al. Biological bases for a possible effect of cannabidiol in Parkinson's disease[J]. Revista Brasileira de Psiquiatria (Sao Paulo,Brazil :1999),2020,42(2):218-224. doi: 10.1590/1516-4446-2019-0460
[5]	Junior N C F,Dos-santos-pereira M,Guimarães F S,et al. Cannabidiol and cannabinoid compounds as potential strategies for treating parkinson's disease and L-DOPA-Induced dyskinesia[J]. Neurotoxicity Research,2020,37(1):12-29. doi: 10.1007/s12640-019-00109-8
[6]	Balash Y,Bar-lev schleider L,Korczyn A D,et al. Medical cannabis in parkinson disease:Real-Life patients' experience[J]. Clinical Neuropharmacology,2017,40(6):268-272. doi: 10.1097/WNF.0000000000000246
[7]	Khan F,Amatya B. Rehabilitation in multiple sclerosis:A systematic review of systematic reviews[J]. Archives of Physical Medicine and Rehabilitation,2017,98(2):353-367. doi: 10.1016/j.apmr.2016.04.016
[8]	López-sendón moreno J L,García caldentey J,Trigo cubillo P,et al. A double-blind,randomized,cross-over,placebo-controlled,pilot trial with Sativex in Huntington's disease[J]. Journal of Neurology,2016,263(7):1390-1400. doi: 10.1007/s00415-016-8145-9
[9]	Clément T,Rodriguez-grande B,Badaut J. Aquaporins in brain edema[J]. Journal of Neuroscience Research,2020,98(1):9-18. doi: 10.1002/jnr.24354
[10]	Hayakawa K,Irie K,Sano K,et al. Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism[J]. Biological & Pharmaceutical Bulletin,2009,32(9):1538-1544.
[11]	高兵兵,吴月奎,马建华,等. 大麻二酚对急性脑出血小鼠的神经保护作用及其机制[J]. 山东医药,2017,57(4):34-36. doi: 10.3969/j.issn.1002-266X.2017.04.010
[12]	Mandolini G M,Lazzaretti M,Pigoni A,et al. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders:a critical overview[J]. Epidemiology and Psychiatric Sciences,2018,27(4):327-335. doi: 10.1017/S2045796018000239
[13]	Zanelati T V,Biojone C,Moreira F A,et al. Antidepressant-like effects of cannabidiol in mice:possible involvement of 5-HT1A receptors[J]. British Journal of Pharmacology,2010,159(1):122-128. doi: 10.1111/j.1476-5381.2009.00521.x
[14]	Ceskova E,Silhan P. Novel treatment options in depression and psychosis[J]. Neuropsychiatric Disease and Treatment,2018,14(1):741-747.
[15]	Silote G P,Sartim A,Sales A,et al. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms[J]. Journal of Chemical Neuroanatomy,2019,98(4):104-116.
[16]	Statter M B,Hirschl R B,Coran A C. Inflammatory bowel disease[J]. Pediatric Clinics of North America,1993,40:1213-1231.
[17]	De filippis D,Iuvone T,D'amico A,et al. Effect of cannabidiol on sepsis-induced motility disturbances in mice:involvement of CB receptors and fatty acid amide hydrolase[J]. Neurogastroenterology and Motility :The official Journal of the European Gastrointestinal Motility Society,2008,20(8):919-927. doi: 10.1111/j.1365-2982.2008.01114.x
[18]	Chen G Y,Cao H X,Li F,et al. New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in east China:Shanghai baosteel cohort[J]. Journal of diabetes investigation,2016,7(2):206-211. doi: 10.1111/jdi.12395
[19]	Wang Y,Mukhopadhyay P,Cao Z,et al. Cannabidiol attenuates alcohol-induced liver steatosis,metabolic dysregulation,inflammation and neutrophil-mediated injury[J]. Scientific Reports,2017,7(1):12064. doi: 10.1038/s41598-017-10924-8
[20]	郭蓉,陈璇,郭鸿彦. 四氢大麻酚和大麻二酚的药理研究进展[J]. 天然产物研究与开发,2017,29(8):1449-1453.
[21]	Wang Y,Mukhopadhyay P,CAO Z,et al. Cannabidiol protects against chronic plus binge alcohol induced liver injury by modulating neutrophil infiltration,E selectin,inflammation and oxidative/nitrative stress[J]. Free Radical Biology & Medicine,2014,76(12):S88.
[22]	Ignatowska-jankowska B,Jankowski M M,Swiergiel A H. Cannabidiol decreases body weight gain in rats:involvement of CB2 receptors[J]. Neuroscience Letters,2011,490(1):82-84. doi: 10.1016/j.neulet.2010.12.031
[23]	Yang L,Rozenfeld R,Wu D,et al. Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy[J]. Free Radic Biol Med,2014,68(3):260-267.
[24]	Silvestri C,Paris D,Martella A,et al. Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis[J]. Journal of Hepatology,2015,62(6):1382-1390. doi: 10.1016/j.jhep.2015.01.001
[25]	陈瑞,高晓刚,张雷,等. 大麻二酚对大鼠非酒精性脂肪肝的治疗作用及机制[J]. 解放军医学杂志,2017,42(6):515-519. doi: 10.11855/j.issn.0577-7402.2017.06.07
[26]	常丽,李建军,黄思齐,等. 植物大麻活性成分及其药用研究概况[J]. 生命的化学,2018,38(2):273-280.
[27]	韦凤,涂冬萍,王柳萍. 火麻仁食用开发和药理作用研究进展[J]. 中国老年学,2015,35(12):3486-3488.
[28]	Oláh A,Tóth B I,Borbíró I,et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes[J]. The Journal of Clinical Investigation,2014,124(9):3713-3724. doi: 10.1172/JCI64628
[29]	Petrosino S,Verde R,Vaia M,et al. Anti-inflammatory properties of cannabidiol,a nonpsychotropic cannabinoid,in experimental allergic contact dermatitis[J]. The Journal of Pharmacology and Experimental Therapeutics,2018,365(3):652-663. doi: 10.1124/jpet.117.244368
[30]	Wilkinson J D,Williamson E M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis[J]. Journal of Dermatological Science,2007,45(2):87-92. doi: 10.1016/j.jdermsci.2006.10.009
[31]	Walsh S K,Hepburn C Y,Kane K A,et al. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion[J]. British Journal of Pharmacology,2010,160(5):1234-1242. doi: 10.1111/j.1476-5381.2010.00755.x
[32]	Durst R,Danenberg H,Gallily R,et al. Cannabidiol,a nonpsychoactive cannabis constituent,protects against myocardial ischemic reperfusion injury[J]. American Journal of Physiology Heart and Circulatory Physiology,2007,293(6):H3602-3607. doi: 10.1152/ajpheart.00098.2007
[33]	Feng Y,Chen F,Yin T,et al. Pharmacologic effects of cannabidiol on acute reperfused myocardial infarction in rabbits:Evaluated with 3.0T cardiac magnetic resonance imaging and histopathology[J]. Journal of Cardiovascular Pharmacology,2015,66(4):354-363. doi: 10.1097/FJC.0000000000000287
[34]	Stanley C P,Hind W H,O'sullivan S E. Is the cardiovascular system a therapeutic target for cannabidiol[J]. British Journal of Clinical Pharmacology,2013,75(2):313-322. doi: 10.1111/j.1365-2125.2012.04351.x
[35]	孙姣卓,王雄,张萍. 大麻二酚对大鼠心肌缺血/再灌注损伤的保护作用和机制[J]. 中西医结合心脑血管病杂志,2016,14(2):133-137. doi: 10.3969/j.issn.1672-1349.2016.02.008
[36]	Blair R E,Deshpande L S,Delorenzo R J. Cannabinoids:is there a potential treatment role in epilepsy[J]. Expert Opinion on Pharmacotherapy,2015,16(13):1911-1914. doi: 10.1517/14656566.2015.1074181
[37]	Ribeiro A,Ferraz-de-paula V,Pinheiro M L,et al. Cannabidiol,a non-psychotropic plant-derived cannabinoid,decreases inflammation in a murine model of acute lung injury:role for the adenosine A(2A) receptor[J]. European Journal of Pharmacology,2012,678(1-3):78-85. doi: 10.1016/j.ejphar.2011.12.043
[38]	叶程龙余,莫斯喻,等. 大麻二酚对应激大鼠肺部损伤的预防保护作用[J]. 广东药学院学报,2019,35(2):234-237.
[39]	JAcobsson S O,Rongård E,Stridh M,et al. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability[J]. Biochemical Pharmacology,2000,60(12):1807-1813. doi: 10.1016/S0006-2952(00)00492-5
[40]	Massi P,Vaccani A,Bianchessi S,et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells[J]. Cellular and Molecular Life Sciences :CMLS,2006,63(17):2057-2066. doi: 10.1007/s00018-006-6156-x
[41]	Shrivastava A,Kuzontkoski P M,Groopman J E,et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy[J]. Molecular Cancer Therapeutics,2011,10(7):1161-1172. doi: 10.1158/1535-7163.MCT-10-1100
[42]	Elbaz M,Nasser M W,Ravi J,et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway:novel anti-tumor mechanisms of cannabidiol in breast cancer[J]. Molecular Oncology,2015,9(4):906-919. doi: 10.1016/j.molonc.2014.12.010
[43]	Haustein M,Ramer R,Linnebacher M,et al. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1[J]. Biochemical pharmacology,2014,92(2):312-325. doi: 10.1016/j.bcp.2014.07.014
[44]	Solinas M,Massi P,Cantelmo A R,et al. Cannabidiol inhibits angiogenesis by multiple mechanisms[J]. British Journal of Pharmacology,2012,167(6):1218-1231. doi: 10.1111/j.1476-5381.2012.02050.x
[45]	Simmerman E,Qin X,Yu J C,et al. Cannabinoids as a potential new and novel treatment for melanoma:A pilot study in a murine model[J]. The Journal of Surgical Research,2019,235(3):210-215.
[46]	Chelliah M P,Zinn Z,Khuu P,et al. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa[J]. Pediatric Dermatology,2018,35(4):e224-e227. doi: 10.1111/pde.13545
[47]	Weiss L,Zeira M,Reich S,et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice[J]. Autoimmunity,2006,39(2):143-151. doi: 10.1080/08916930500356674
[48]	Weiss L,Zeira M,Reich S,et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice[J]. Neuropharmacology,2008,54(1):244-249. doi: 10.1016/j.neuropharm.2007.06.029
[49]	Huestis M A,Solimini R,Pichini S,et al. Cannabidiol adverse effects and toxicity[J]. Current Neuropharmacology,2019,17(10):974-989. doi: 10.2174/1570159X17666190603171901

计量

文章访问数: 1990
HTML全文浏览量: 1797
PDF下载量: 24
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

大麻二酚在医学上的应用前景

doi: 10.12259/j.issn.2095-610X.S20210208

作者简介:
蒋鸿雁（1993～），女，四川遂宁人，在读硕士研究生，主要从事人体解剖学与组织胚胎学研究工作

通讯作者:
李坪，E-mail：kyzplp@163.com

计量

Application Prospect of Mannabidiol in Medicine

计量

目录

[1]	王秀花, 何泽然, 李志蕻, 王慧铃, 苏红艳. 脂肪乳氨基酸（17）葡萄糖（11%）注射液临床应用点评与规范、合理使用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230318
[2]	寸睿, 陈美玲. 氟桂利嗪联合银杏达莫治疗老年眩晕的疗效及临床应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220703
[3]	杨淑迪, 钟雨莉, 刘玲, 田新. 加速康复外科在新生儿围手术期管理中的应用与展望, 昆明医科大学学报.
[4]	孙孔春, 陈兴龙, 杨璨瑜, 于浩飞, 胡炜彦, 王蕊, 沈报春, 张荣平. 不同条件下工业大麻中大麻二酚含量变化, 昆明医科大学学报.
[5]	宁金梅, 钮燕, 赵树波, 朱媛, 朱恒杰, 汤勇. 外伤性鼓膜穿孔贴补治疗的对比, 昆明医科大学学报.
[6]	杨玥, 陶建平. 右美托咪定的临床麻醉应用进展, 昆明医科大学学报.
[7]	王秀花, 杨重明, 杨超, 张光云, 任东伟, 王学昌. 临沧市人民医院抗肿瘤药物临床应用评价, 昆明医科大学学报.
[8]	邓立强. 七氟醚和异丙酚对单肺通气致缺血-再灌注损伤保护作用的比较, 昆明医科大学学报.
[9]	高文秀. 氟保护漆Duraphat的临床应用, 昆明医科大学学报.
[10]	周莹. 二代测序技术在临床医学上的相关应用, 昆明医科大学学报.
[11]	李建钢. 改良视可尼喉镜插管法在颈椎手术气管插管中的临床应用, 昆明医科大学学报.
[12]	王参智. MGMT、XRCC1基因在脑胶质瘤中的表达及其临床应用, 昆明医科大学学报.
[13]	于洋. 神经生长因子NGF的神经元保护作用机制及临床应用研究现状, 昆明医科大学学报.
[14]	李建钢. 视可尼纤维喉镜在困难气道中的临床应用, 昆明医科大学学报.
[15]	杜雄. CgA 和 PCA3的表达在前列腺癌患者诊断中的应用研究, 昆明医科大学学报.
[16]	张洪江. 经阴道彩超诊断宫内组织残留的临床分析, 昆明医科大学学报.
[17]	宋超. 多层螺旋CT对结、直肠息肉检查的临床应用, 昆明医科大学学报.
[18]	. 胶囊内镜在消化道疾病的临床应用, 昆明医科大学学报.
[19]	. 系统化全程健康教育在PICC置管患者中的临床应用研究, 昆明医科大学学报.
[20]	孙杰. 去骨瓣减压术的临床应用, 昆明医科大学学报.

留言板

大麻二酚在医学上的应用前景

doi: 10.12259/j.issn.2095-610X.S20210208

作者简介: 蒋鸿雁（1993～），女，四川遂宁人，在读硕士研究生，主要从事人体解剖学与组织胚胎学研究工作

通讯作者: 李坪，E-mail：kyzplp@163.com

计量

出版历程

Application Prospect of Mannabidiol in Medicine

计量

出版历程

目录

作者简介:
蒋鸿雁（1993～），女，四川遂宁人，在读硕士研究生，主要从事人体解剖学与组织胚胎学研究工作

通讯作者:
李坪，E-mail：kyzplp@163.com